DEF 14A: Core Laboratories Seeks Shareholder Approval for Amended Long-Term Incentive Plan

Core Laboratories is asking shareholders to approve an amendment and restatement of its 2020 Long-Term Incentive Plan to increase the number of authorized shares and extend the plan's term.

Summary

• Core Laboratories is seeking shareholder approval to amend and restate its 2020 Long-Term Incentive Plan (LTIP).
• The primary goals are to increase the authorized shares by 1,100,000 and extend the plan's term through May 8, 2034.
• As of February 29, 2024, 374,871 shares were available for issuance under the existing plan.
• The company aims to limit annual dilution from the LTIP to less than 2.0%.
• The company's annual dilution was approximately 1.01% in 2023, 0.49% in 2022 and 0.49% in 2021.
• If approved, the amended plan will be called the Core Laboratories Inc. 2024 Long-Term Incentive Plan.
• The maximum number of shares subject to awards granted to one individual per calendar year is 1,600,000.
• The board has set a minimum vesting period for time-based awards at three years and for performance-based awards at one year.
• The company's long-term plan is to limit annual dilution from the 2024 LTIP to less than 2.0%.

Sentiment

Score: 7

Explanation: The document is neutral to positive. It outlines a standard corporate governance procedure (amending a long-term incentive plan) with the goal of aligning employee and shareholder interests. There are no significant red flags or negative indicators.

Positives

• The amended LTIP aims to align employee incentives with long-term shareholder value creation.
• The company's long-term plan is to limit annual dilution from the 2024 LTIP to less than 2.0%.
• The board has set a minimum vesting period for time-based awards at three years and for performance-based awards at one year.

Negatives

• Failure to approve the plan may require the company to use cash compensation, which may not align with shareholder interests.
• The company's annual dilution was approximately 1.01% in 2023, 0.49% in 2022 and 0.49% in 2021.

Risks

• If the plan is not approved, the company may face challenges in attracting and retaining qualified personnel.
• Using cash compensation instead of equity awards could increase cash compensation expense and reduce funds for reinvestment or shareholder returns.
• The company's annual dilution was approximately 1.01% in 2023, 0.49% in 2022 and 0.49% in 2021.

Future Outlook

The company intends to register the additional shares for the 2024 LTIP on a Form S-8 Registration Statement if approved.

Industry Context

Long-term incentive plans are common in the industry to align employee compensation with company performance and shareholder value.

Comparison to Industry Standards

• The company's long-term plan is to limit annual dilution from the 2024 LTIP to less than 2.0%.
• The board has set a minimum vesting period for time-based awards at three years and for performance-based awards at one year.

Stakeholder Impact

• Approval of the plan is intended to benefit shareholders by aligning employee incentives with long-term value creation.
• Employees may benefit from the opportunity to receive equity awards under the plan.

Next Steps

• Shareholder vote on the proposed amendment and restatement of the 2020 Long-Term Incentive Plan at the 2024 Annual Meeting.
• If approved, the company will register the additional shares on a Form S-8 Registration Statement.

Key Dates

Keywords

Long-Term Incentive Plan, Shareholder Approval, Equity Awards, Compensation, Dilution, Vesting, Core Laboratories